BRAF Mutation and Cancer - Johns Hopkins Medicine
The Johns Hopkins BRAF Brain Tumor Center unites experts across neurosurgery and oncology to treat cancers of the brain caused by BRAF mutations. Additionally, the center participates in several clinical trials to better understand these tumors and identify new ways to address them.
BRAF Mutation: Cancer Types, Testing, Treatment - Verywell Health
2024年6月23日 · BRAF mutations are DNA changes in some cancer cells that can be treated with newer targeted therapies. BRAF mutations are found in roughly half of melanomas. Medications that target these mutations have significantly improved the survival rates of metastatic melanoma.
FDA approves dabrafenib–trametinib for BRAF-positive cancers
2022年7月21日 · FDA previously approved the dabrafenib–trametinib combination for the treatment of people with advanced forms of specific cancers whose tumors have the BRAF V600E mutation, including non-small cell lung cancer, melanoma, and anaplastic thyroid cancer.
BRAF
2024年4月16日 · In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF...
BRAF (gene) - Wikipedia
BRAF is a human gene that encodes a protein called B-Raf. The gene is also referred to as proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B, while the protein is more formally known as serine/threonine-protein kinase B-Raf. [5][6]
BRAF — a tumour-agnostic drug target with lineage-specific
2024年1月26日 · In this Review, we describe the biochemical basis for oncogenic BRAF-induced activation of MAPK signalling and pan-cancer and lineage-specific mechanisms of intrinsic, adaptive and acquired...
BRAF Brain Tumor Center - Johns Hopkins Medicine
Evaluate and treat patients with BRAF-mutated primary brain tumors. Explore the role of new pathway inhibitors that might help treat these patients. Partner with our basic science colleagues to discover mechanisms of resistance, clinically relevant targets and new pathway-specific drugs.
Molecular Pathways and Mechanisms of BRAF in Cancer Therapy
2022年11月1日 · With the identification of activating mutations in BRAF across a wide variety of malignancies, substantial effort was placed in designing safe and effective therapeutic strategies to target BRAF.
BRAF-Targeted Drug Approved for Pediatric Low-Grade Glioma
2024年5月28日 · On April 23, the Food and Drug Administration (FDA) granted accelerated approval to tovorafenib (Ojemda) for kids aged 6 months or older who have low-grade glioma, a type of brain tumor, with changes in a gene called BRAF.
BRAF and MEK Inhibitors for Active or Symptomatic Melanoma …
Mutations in genes such as BRAF and cell proliferation controlled by enzymes such as MEK play crucial roles in promoting cell survival, proliferation, and metastasis. 9 BRAF and MEK inhibitors are targeted therapies used to treat metastatic melanoma, including cases where the cancer has metastasized to the brain. 10 BRAF inhibitors, such as ...